Ascendis Pharma Reports First Quarter 2024 Financial Results

— Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercia...

Related Keywords

Denmark , United Kingdom , Germany , Austria , Copenhagen , Køavn , United States , American , Great Britain , Tim Lee , Jan Mikkelsen , Melinda Baker , Ascendis Pharma , Patti Bank , American Society For Clinical Oncology , Exchange Commission , Chief Executive , Endocrinology Rare Disease , Metabolic Diseases , European Economic Area , Biologics License Application , Prescription Drug User Fee Act , New Drug Application , Believe Trial , American Society , Clinical Oncology , Outlook Based , Current Plans , Months Ended March , Eastern Time , Ascendi Annual Report , Comprehensive Income ,